FDA Peptide Panel Could Reshape Access, Safety Rules and a Multibillion-Dollar Market

Nearly two years after Robert F. Kennedy Jr. vowed to end the FDA’s “war” on peptides, an unusual FDA advisory committee is weighing the future of several popular compounds. The panel is evaluating seven peptides that the FDA recently barred US compounding pharmacies from preparing. On July 23, the first day of a two-day meeting, the panel voted to approve BPC-157, known as the “wolverine” shot and marketed for recovery and wound healing. Other peptides under discussion include TB-500 and epitalon.

Peptides are signaling molecules that are not long enough to be considered proteins, and the body produces thousands of them daily. Some peptides, including insulin, GLP-1 drugs and tesamorelin, are already FDA-approved for certain conditions. The compounds now being debated are different: lesser-studied injections that have gained traction in fitness and wellness circles for uses tied to injury recovery, fat loss and sleep. The FDA’s position is that each peptide needs its own safety and efficacy review, similar to a drug.

The FDA has raised concerns about immune reactions and the lack of evidence that the reviewed peptides work as promoted. In 2023, 19 peptides were removed from the list of substances US compounding pharmacies can legally prepare because of safety concerns. Industry advocates argue that demand already exists and that tighter standards for purity and potency could create a safer supply than the gray “research purposes only” market. The debate is less about whether peptides are popular and more about how regulators should handle products with uneven clinical evidence.

Business Insider reports that a loosening of FDA restrictions could open a multibillion-dollar market for telehealth companies and compounders, with Hims & Hers viewed as one company positioned to benefit if pharmacies can compound more peptides. The committee’s makeup is also drawing scrutiny because several members prescribe, research or sell peptide therapies. Peter Lurie of the Center for Science in the Public Interest told Business Insider it is “unheard of” for someone selling a product to vote on an advisory committee on that product. Although the committee’s decisions are non-binding, the FDA has historically followed its recommendations.

Business Insider identified six peptide-prescribing doctors and clinic heads who could potentially gain business from the panel’s decisions: Gabriel Alizaidy, Dr. Asare Christian, Melissa Loseke, Dr. Haleem Mohammed, Dr. Joshua Starbuck and Dr. Kris Wusterhausen. Their roles range from telehealth and longevity clinics to medical-director positions at practices offering peptide therapy. For readers, the key takeaway is to watch both the scientific conclusions and the conflict-of-interest questions because both could shape how the FDA responds after the meeting.